Reductions in myeloid-derived suppressor cells and lung metastases using AZD4547 treatment of a metastatic murine breast tumor model

Cellular Physiology and Biochemistry

Volumn 33, Issue 3, 2014, Pages 633-645

  Liu, Li ^a   Ye, Ting Hong ^a   Han, Yuan Ping ^a   Song, Hang ^a   Zhang, Yong Kui ^a   Xia, Yong ^b   Wang, Ning Yu ^b   Xiong, Ying ^b   Song, Xue Jiao ^b   Zhu, Yong Xia ^b   Li, De Liang ^b   Zeng, Jun ^b   Ran, Kai ^b   Peng, Cui Ting ^a,b   Wei, Yu Quan ^b   Yu, Luo Ting ^a,b  

^a SICHUAN UNIVERSITY   (China)

^b SICHUAN UNIVERSITY   (China)

Author keywords

AZD4547; Breast cancer; FGFR inhibitor; MDSCs; Metastasis; T cells

Indexed keywords

AZD 4547; CD4 ANTIGEN; CD8 ANTIGEN; BENZAMIDE DERIVATIVE; PIPERAZINE DERIVATIVE; PYRAZOLE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; BONE MARROW CELL; BREAST TUMOR; CANCER INHIBITION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL INFILTRATION; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LUNG METASTASIS; LUNG PARENCHYMA; METASTASIS INHIBITION; MOUSE; MYELOID DERIVED SUPPRESSOR CELL; NONHUMAN; PRIORITY JOURNAL; SPLEEN; TUMOR MICROENVIRONMENT; TUMOR MODEL; ANIMAL; DRUG SCREENING; IMMUNOLOGY; LUNG NEOPLASMS; MAMMARY NEOPLASMS, EXPERIMENTAL; METASTASIS; PATHOLOGY; PROCEDURES; TUMOR CELL LINE; ANIMAL TISSUE; SUPPRESSOR CELL; TUMOR CELL;

ANIMALIA; MURINAE; MUS;

ANIMALS; BENZAMIDES; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; HUMANS; LUNG NEOPLASMS; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MYELOID CELLS; NEOPLASM METASTASIS; PIPERAZINES; PYRAZOLES;

EID: 84895932502     PISSN: 10158987     EISSN: 14219778     Source Type: Journal    
DOI: 10.1159/000358640     Document Type: Article

References (36)

1. Siegel R, Naishadham D, Jemal A: Cancer statistics, 2013. CA: Cancer J Clin 2013;63:11-30.
2. Wang W, Eddy R, Condeelis J: The cofilin pathway in breast cancer invasion and metastasis. Nat Rev Cancer 2007;7:429-440.
3. Zhang T, Li J, Dong Y, Zhai D, Lai L, Dai F, Deng H, Chen Y, Liu M, Yi Z: Cucurbitacin E inhibits breast tumor metastasis by suppressing cell migration and invasion. Breast Cancer Res Tr 2012;135:445-458.
4. Yan HH, Pickup M, Pang Y, Gorska AE, Li Z, Chytil A, Geng Y, Gray JW, Moses HL, Yang L: Gr-1+ CD11b+ myeloid cells tip the balance of immune protection to tumor promotion in the premetastatic lung. Cancer Res 2010;70:6139-6149.
5. Place AE, Jin Huh S, Polyak K: The microenvironment in breast cancer progression: biology and implications for treatment. Breast Cancer Res 2011;13:227-238.
6. Cheng P, Corzo CA, Luetteke N, Yu B, Nagaraj S, Bui MM, Ortiz M, Nacken W, Sorg C, Vogl T: Inhibition of dendritic cell differentiation and accumulation of myeloid-derived suppressor cells in cancer is regulated by S100A9 protein. J Exp Med 2008;205:2235-2249.
7. Ostrand-Rosenberg S, Sinha P: Myeloid-derived suppressor cells: linking inflammation and cancer. J Immunol 2009;182:4499-4506.
8. Gabrilovich DI, Nagaraj S: Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 2009;9:162-174.
9. Kodumudi KN, Woan K, Gilvary DL, Sahakian E, Wei S, Djeu JY: A novel chemoimmuno modulating property of docetaxel: suppression of myeloid-derived suppressor cells in tumor bearers. Clin Cancer Res 2010;1618:4583-4594.
10. Dolcetti L, Marigo I, Mantelli B, Peranzoni E, Zanovello P, Bronte V: Myeloid-derived suppressor cell role in tumor-related inflammation. Cancer Lett 2008;267:216-225.
11. Dugast A-S, Haudebourg T, Coulon F, Heslan M, Haspot F, Poirier N, de Silly RV, Usal C, Smit H, Martinet B: Myeloid-derived suppressor cells accumulate in kidney allograft tolerance and specifically suppress effector T cell expansion. J Immunol 2008;180:7898-7906.
12. Ray ME, Yang ZQ, Albertson D, Kleer CG, Washburn JG, Macoska JA, Ethier SP: Genomic and expression analysis of the 8p11-12 amplicon in human breast cancer cell lines. Cancer Res 2004;64:40-47.
13. Keats JJ, Reiman T, Belch AR, Pilarski LM: Ten years and counting: so what do we know about t (4; 14)(p16; q32) multiple myeloma. Leukemia Lymphoma 2006;47:2289-2300.
14. Pollock P, Gartside M, Dejeza L, Powell M, Mallon M, Davies H, Mohammadi M, Futreal P, Stratton M, Trent J: Frequent activating FGFR2 mutations in endometrial carcinomas parallel germline mutations associated with craniosynostosis and skeletal dysplasia syndromes. Oncogene 2007;26:7158-7162.
15. Jang J-H, Shin K-H, Park J-G: Mutations in fibroblast growth factor receptor 2 and fibroblast growth factor receptor 3 genes associated with human gastric and colorectal cancers. Cancer Res 2001;61:3541-3543.
16. Sahadevan K, Darby S, Leung H, Mathers M, Robson C, Gnanapragasam V: Selective over-expression of fibroblast growth factor receptors 1 and 4 in clinical prostate cancer. J Pathol 2007;213:82-90.
17. Zhang J, Zhang L, Su X, Li M, Xie L, Malchers F, Fan S, Yin X, Xu Y, Liu K: Translating the Therapeutic Potential of AZD4547 in FGFR1-Amplified Non-Small Cell Lung Cancer through the Use of Patient-Derived Tumor Xenograft Models. Clin Cancer Res 2012;18:6658-6667.
18. Xie L, Su X, Zhang L, Yin X, Tang L, Zhang X, Xu Y, Gao Z, Liu K, Zhou M: FGFR2 gene amplification in gastric cancer predicts sensitivity to the selective FGFR inhibitor AZD4547. Clin Cancer Res 2013;19:2572-2583.
19. Chen X, Ji P, Yang H-W, Yang L-L, Zhou S, Zhong L, Ma S, Fu X-Y, Zhou C, Li G-B: SC-535, a Novel Oral Multikinase Inhibitor, Showed Potent Antitumor Activity in Human Melanoma Models. Cell Physiol Biochem 2013;32:138-153.
20. Yi ZF, Cho SG, Zhao H, Wu Yy, Luo J, Li D, Yi T, Xu X, Wu Z, Liu M: A novel peptide from human apolipoprotein (a) inhibits angiogenesis and tumor growth by targeting c-Src phosphorylation in VEGF-induced human umbilical endothelial cells. Int J Cancer 2009;124:843-852.
21. Dai XY, Zeng XX, Peng F, Han YY, Lin HJ, Xu YZ, Zhou T, Xie G, Deng Y, Mao YQ Yu LY, Yang L, Zhao YL: A novel anticancer agent, sklb70359, inhibits human hepatic carcinoma cells proliferation via g0/g1 cell cycle arrest and apoptosis induction. Cell Physiol Biochem 2012;29:281-290.
22. Xuejiao S, Yong X, Ningyu W, Lidan Z, Xuanhong S, Youzhi X, Tinghong Y, Yaojie S, Yongxia Z, Luoting Y: A Novel Benzothiazole Derivative YLT322 Induces Apoptosis via the Mitochondrial Apoptosis Pathway In Vitro with Anti-Tumor Activity in Solid Malignancies. PloS One 2013;8:e63900.
23. Kortylewski M, Kujawski M, Wang T, Wei S, Zhang S, Pilon-Thomas S, Niu G, Kay H, Mulé J, Kerr WG: Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity. Nat Med 2005;11:1314-1321.
24. Gavine PR, Mooney L, Kilgour E, Thomas AP, Al-Kadhimi K, Beck S, Rooney C, Coleman T, Baker D, Mellor MJ: AZD4547: an orally bioavailable, potent, and selective inhibitor of the fibroblast growth factor receptor tyrosine kinase family. Cancer Res 2012;72:2045-2056.
25. Li J-S, Yao Z-X: Modulation of FGF receptor signaling as an intervention and potential therapy for myelin breakdown in Alzheimer's disease. Med Hypotheses 2013.
26. Dey JH, Bianchi F, Voshol J, Bonenfant D, Oakeley EJ, Hynes NE: Targeting fibroblast growth factor receptors blocks PI3K/AKT signaling, induces apoptosis, and impairs mammary tumor outgrowth and metastasis. Cancer Res 2010;70:4151-4162.
27. Ye T, Wei X, Yin T, Xia Y, Li D, Shao B, Song X, He S, Luo M, Gao X: Inhibition of FGFR signaling by PD173074 improves antitumor immunity and impairs breast cancer metastasis. Breast Cancer Res Tr DOI: 10.1007/s10549-013-2829-y.
28. Pulaski BA, Ostrand-Rosenberg S: Mouse 4T1 breast tumor model. Curr Protoc Immunol Doi: 10.1002/0471142735.im2002s39.
29. Tu Z, Ma Y, Tian J, Li H, Akers W, Achilefu S, Gu Y: Estrogen receptor β potentiates the antiproliferative effect of raloxifene and affects the cell migration and invasion in HCT-116 colon cancer cells. J Cancer Res Clin Oncol 2012;138:1091-1103.
30. Yang L, DeBusk LM, Fukuda K, Fingleton B, Green-Jarvis B, Shyr Y, Matrisian LM, Carbone DP, Lin PC: Expansion of myeloid immune suppressor Gr+ CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis. Cancer Cell 2004;6:409-421.
31. Zhang B, Ma X, Li Z, Gao X, Wang F, Liu L, Shen G, Sang Y, Li M, Li Y: Celecoxib enhances the efficacy of 15-hydroxyprostaglandin dehydrogenase gene therapy in treating murine breast cancer. J Cancer Res Clin Oncol 2013;1-11.
32. Xin H, Herrmann A, Reckamp K, Zhang W, Pal S, Hedvat M, Zhang C, Liang W, Scuto A, Weng S: Antiangiogenic and antimetastatic activity of JAK inhibitor AZD1480. Cancer Res 2011;71:6601-6610.
33. Liao D, Luo Y, Markowitz D, Xiang R, Reisfeld RA: Cancer associated fibroblasts promote tumor growth and metastasis by modulating the tumor immune microenvironment in a 4T1 murine breast cancer model. PLoS One 2009;4:e7965.
34. Tiong KH, Mah LY, Leong C-O: Functional roles of fibroblast growth factor receptors (FGFRs) signaling in human cancers. Apoptosis 2013:1-22.
35. Valesky M, Spang AJ, Fisher GW, Farkas DL, Becker D: Noninvasive dynamic fluorescence imaging of human melanomas reveals that targeted inhibition of bFGF or FGFR-1 in melanoma cells blocks tumor growth by apoptosis. Mol Med 2002;8:103-112.
36. Park CC: The Stromal Microenvironment and Breast Cancer Biology. Breast Diseases: A Year Book Quarterly 2013;24:23-27.